Alkem Laboratories Ltd has launched Empanorm, a generic version of empagliflozin, at prices nearly 80% lower than innovator products. Empagliflozin is a widely used SGLT-2 inhibitor for managing type-2 diabetes, chronic kidney disease (CKD), and heart failure (HF).
With a patient-first approach, Alkem has incorporated advanced anti-counterfeit security bands on Empanorm packaging. Patients also receive bilingual educational materials (Hindi & English) and QR codes providing detailed information on diabetes, CKD, and HF in 11 languages.
Alkem has designed smaller tablet sizes for greater convenience while maintaining bioequivalence to innovator drugs. The product line includes:
- Empanorm (Empagliflozin)
- Empanorm L (Empagliflozin + Linagliptin)
- Empanorm Duo / Alsita E (Empagliflozin + Sitagliptin)
- Empanorm M (Empagliflozin + Metformin)
By offering high-quality, cost-effective diabetes and CKD management solutions, Alkem aims to improve accessibility for millions of patients in India.
Dr. Vikas Gupta, CEO, Alkem, commented, “As we expand and strengthen our chronic portfolio, the introduction of generic empagliflozin in India is an important milestone. This globally-accepted molecule has transformed diabetes care with its additional benefits in managing chronic kidney disease and cardiovascular health. Leveraging Alkem’s strong distribution network, we aim to make this therapy widely available, enhancing treatment accessibility and improving health outcomes for patients across the country.”
